This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie (ABBV) Stock Moves -1.54%: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $93.11, marking a -1.54% move from the previous day.
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
by Zacks Equity Research
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study
by Zacks Equity Research
J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.
AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis
by Zacks Equity Research
AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.
Roche's Hemlibra Receives FDA Approval for Label Expansion
by Zacks Equity Research
Roche (RHHBY) obtains the FDA approval for the label expansion of Hemlibra for the treatment of adults and children suffering haemophilia A without factor VIII inhibitors.
Gilead Announces Positive Data From Ongoing Biktarvy Study
by Zacks Equity Research
Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors
by Zacks Equity Research
To boost its pipeline, Gilead (GILD) collaborates with HiFiBiO Therapeutics for the development of T-cell receptors.
Here's Why J&J (JNJ) is a Good Bet in a Troubled Market
by Zacks Equity Research
A diversified portfolio, robust pipeline, strong growth of new drugs and a consistent dividend payout make Johnson & Johnson (JNJ) a good bet amid market turmoil as well as over the long term.
Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck & Other Pharma Players Await FDA Decisions in October
by Kinjel Shah
FDA grants approval to 41 new treatments till the end of September.
The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental
Top Analyst Reports for ExxonMobil, Disney & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil (XOM), Disney (DIS), and AbbVie (ABBV).
AbbVie (ABBV) Stock Moves 0.47%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $94.60, moving +0.47% from the previous trading session.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Gilead (GILD) to Launch Generics for Leading HCV Treatments
by Zacks Equity Research
Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.
AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU
by Zacks Equity Research
The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $92.05, marking a -0.51% move from the previous day.
Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.
Company News For Sep 20, 2018
by Zacks Equity Research
Companies In The News are: TLRY,FB,CPRT,ABBV
Bristol-Myers' MM Drug Empliciti Application Validated by EMA
by Zacks Equity Research
Bristol-Myers' (BMY) application for multiple myeloma drug, Empliciti gets validated in Europe.
AbbVie Faces California Insurance Department Suit for Humira
by Zacks Equity Research
AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
by Zacks Equity Research
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
Roche's Child Arthritis Drug's New Formulation Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.